Focusing on independent core innovation is the only way for high-tech enterprises to achieve long-term global competitiveness, Song Ning, founder of Diagens Biotech, told Yicai in an exclusive interview. The Chinese AI medtech firm [HKG: 2526] opened 121% above its IPO price on its trading debut yesterday.